Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBIT (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed EBIT for 11 consecutive years, with -$19.4 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 32.8% to -$19.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$94.0 million through Dec 2025, up 22.54% year-over-year, with the annual reading at -$94.0 million for FY2025, 22.54% up from the prior year.
  • EBIT hit -$19.4 million in Q4 2025 for Seres Therapeutics, up from -$22.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $68.4 million in Q3 2021 to a low of -$70.6 million in Q1 2023.
  • Historically, EBIT has averaged -$28.1 million across 5 years, with a median of -$31.8 million in 2024.
  • Biggest five-year swings in EBIT: surged 328.06% in 2021 and later plummeted 2038.88% in 2023.
  • Year by year, EBIT stood at -$49.4 million in 2021, then surged by 96.5% to -$1.7 million in 2022, then tumbled by 2038.88% to -$37.0 million in 2023, then rose by 22.12% to -$28.8 million in 2024, then surged by 32.8% to -$19.4 million in 2025.
  • Business Quant data shows EBIT for MCRB at -$19.4 million in Q4 2025, -$22.5 million in Q3 2025, and -$24.9 million in Q2 2025.